<DOC>
	<DOCNO>NCT01225211</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , pharmacokinetics ( PK ) pharmacodynamic ( PD ) effect lumacaftor ( VX-809 ) alone coadministered ivacaftor ( VX-770 ) participant cystic fibrosis , homozygous heterozygous F508del-CFTR mutation .</brief_summary>
	<brief_title>Study VX-809 Alone Combination With VX-770 Cystic Fibrosis ( CF ) Patients Homozygous Heterozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female participant confirm diagnosis CF Must F508delCFTR mutation least 1 allele . FEV1 great equal ( &gt; = ) 40 % predict normal age , gender , height ( Knudson standard ) ( Cohort 1 , 2 , 3 ) ; FEV1 4090 % predict normal age , gender , height ( Hankinson standard ( Cohort 4 ) Participant childbearing potential sexually active must meet contraception requirement History illness condition , opinion investigator might confound result study pose additional risk administer study drug participant ( e.g. , cirrhosis portal hypertension ) . An acute illness include acute upper low respiratory infection , pulmonary exacerbation change therapy ( include antibiotic ) pulmonary disease within 14 day ( Cohort 1 , 2 , 3 ) 28 day ( Cohort 4 ) receive first dose study drug . History solid organ hematological transplantation . History alcohol abuse drug addiction past year , include cannabis , cocaine , opiates . Ongoing participation another therapeutic clinical study , prior participation investigational drug study without appropriate washout Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception Participants enrol Cohort 1 Cohort 2 eligible Cohort 3 Ongoing prior participation investigational drug study within 30 day Screening Visit Heterozygous participant participate Cohort 2 meet eligibility criterion Cohort 4 may participate Cohort 4 Evidence lens opacity cataract determine ophthalmologic examination ( Cohort 4 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>